ReviewCureus2025

Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.

Arwa Alghamdi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.